Minutes - Medication WG 2022-06-21

From Health Level 7 Belgium Wiki
Revision as of 09:24, 21 June 2022 by KarlienErauw (talk | contribs) (Created page with "===== '''Attendees''' ===== * Annemieke Vergauwe * Bart Decuypere * Jean-Michel Polfliet * Jens Penny * José Costa Teixeira * Karlien Erauw * Pablo Christiaens * Tom He...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Attendees
  • Annemieke Vergauwe
  • Bart Decuypere
  • Jean-Michel Polfliet
  • Jens Penny
  • José Costa Teixeira
  • Karlien Erauw
  • Pablo Christiaens
  • Tom Henkens
Excused/Not present
  • Anne Nerenhausen
  • Bruno Casneuf
  • Dieter Sauvillers
  • Elhassan Baazizi
  • Hanne Vuegen
  • Jan Lenie
  • Jean-Louis Maggetto
  • Katrien Thorré
  • Lars Vanreppelen
  • Marc Buckens
  • Nick Hermans
  • Nils Devos
  • Richard Francken
  • Thomas Van Langendonck
  • Tom De Backer
  • Walter Bollaert
  • Will van Norel
Agenda
  • Future of medication scheme
Minutes
  • Work on business rules is still ongoing at RIZIV end
  • before we said that it has to be part of the implementation guide
  • however, can we go and publish the medication scheme ?
  • goal is for prescribor applications to start using the medication treatment
  • We need some documentation for the migration from Kmehr to FHIR: input is needed
  • We have to complexities of contraindications and (drug) allergies & intolerances
  • drug allergies & intolerances are related to decision support, therefore might not be needed to include in the medication scheme but offer as additional service
  • modelling of contraindications needs still to be determined, which can also be temporarily (f.e. pregnancy, breastfeeding)
  • allergy & intolerance will be the way to present this kind of info
  • there are 2 types for which distinction need to be made: patient related & drug related
  • patient's condition is part of medical history (f.e. epilepsy)
  • SAM viewer, there is VNP, CNK etc
  • how many tables are there in the database ?
  • this is the hierarchy: vmp-group > AMP > AMPP > CNK (old)
  • concepts to be uses in MS will have to be defined
  • f.e. support substances ?
  • Jens will have a look

Agenda items for next meeting

  • Current state of profiles on medication view and treatment lines and how it all works at operational level
  • Review made changes
  • Collect feedback on contraindications
  • Identifying business rules

Next meeting July 5 at 11AM